Related Experiment Video

Updated: Jul 19, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

[Treatment for Helicobacter pylori in children. Recent advances]

Elena Lionettil, Stefania Fico, Giovanni Maurogiovanni

    Recenti Progressi in Medicina
    |October 5, 2006
    PubMed

    Insights

    Helicobacter pylori (H. pylori) infection is common, with limited treatment success. Probiotics show promise in managing H. pylori levels and reducing antibiotic side effects.

    Area of Science:

    • Microbiology
    • Infectious Diseases
    • Gastroenterology

    Background:

    • Helicobacter pylori is a prevalent pathogen linked to gastric ulcers and cancer.
    • Current antibiotic treatments for H. pylori are often ineffective due to resistance and poor compliance.
    • Pediatric H. pylori infections are frequently asymptomatic and untreated.

    Discussion:

    • Dual and triple therapies show variable efficacy, with sequential treatments emerging as more effective.
    • Proton pump inhibitor-based triple therapies demonstrate consistent efficacy regardless of duration.
    • Bismuth-based and proton pump inhibitor-based triple therapies show similar effectiveness to certain dual therapies.

    Key Insights:

    • Antibiotic resistance and patient compliance significantly impact H. pylori eradication rates.
    • Sequential treatment regimens offer improved efficacy over standard therapies.
    • Probiotics may help control H. pylori colonization and mitigate antibiotic-related adverse effects.

    Outlook:

    • Probiotics present a potential low-cost, scalable strategy for managing H. pylori, especially in at-risk populations.
    • Further research into probiotic efficacy in combination with antibiotics is warranted.
    • Developing novel therapeutic approaches is crucial for combating H. pylori-associated diseases.

    More Related Videos

    Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance06:40

    Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

    Published on: July 28, 2023

    Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis04:56

    Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

    Published on: May 16, 2025

    Related Concept Videos

    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

    Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
    Peptic Ulcer Disease IV: Management01:26

    Peptic Ulcer Disease IV: Management

    Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
    The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
    Pharmacological management
    The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
    Peptic Ulcer01:27

    Peptic Ulcer

    Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
    Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

    Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

    Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
    Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
    Peptic Ulcer Disease II: Pathophysiology01:24

    Peptic Ulcer Disease II: Pathophysiology

    Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
    Peptic Ulcer Disease II: Pathophysiology01:28

    Peptic Ulcer Disease II: Pathophysiology

    Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
    Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.